77481-28-8

Usage

Uses

Used in Pharmaceutical Synthesis:
N-Methyl-D-glutamic acid is utilized as a building block in the synthesis of various pharmaceutical compounds, leveraging its unique structural and functional properties to enhance the efficacy and specificity of drugs.
Used in Neurological Disorder Treatment:
Recognized for its role in neurotransmission modulation, N-Methyl-D-glutamic acid is explored as a potential therapeutic agent for the treatment of neurological disorders, aiming to alleviate symptoms and improve patient outcomes.
Used in Drug Delivery Systems:
N-Methyl-D-glutamic acid is investigated for its potential as a component in drug delivery systems, where it may contribute to the controlled release, targeting, and overall effectiveness of therapeutic agents, particularly in the treatment of various diseases.
Used in Peptide and Protein Synthesis:
As a derivative of glutamic acid, N-Methyl-D-glutamic acid is employed in the synthesis of peptides and proteins, where its modified properties can influence the structure, stability, and function of these biological molecules, broadening their applications in research and medicine.

Upstream product

• 328-50-7 α-ketoglutaric acid 
• 74-89-5 methylamine 
• 151-50-8 potassium cyanide 
• 56618-13-4 N-benzyloxycarbonyl-N-methyl-DL-glutamic acid 
• 51053-41-9 β-Lipomycin 
• 1187551-30-9 grassystatin C 
• 1572177-01-5 tasiamide C 
• 1572177-02-6 tasiamide D 
• 1572177-03-7 tasiamide E 
• 6893-26-1 D-Glutamic acid 
• 77-78-1 dimethyl sulfate 
• 56-86-0 L-glutamic acid 
• 1155-62-0 N-benzyloxycarbonyl-DL-glutamic acid 
• 19525-56-5 4-(2-CARBOXY-ETHYL)-5-OXO-OXAZOLIDINE-3-CARBOXYLIC ACID BENZYL ESTER 

Relevant academic research and scientific papers

Stellettapeptins A and B, HIV-inhibitory cyclic depsipeptides from the marine sponge Stelletta sp.

Two new HIV-inhibitory depsipeptides, stellettapeptins A (1) and B (2), were isolated from an extract of the marine sponge Stelletta sp., collected from northwestern Australia. Structures of these cyclic nonribosomal peptides were elucidated on the basis of extensive NMR data analysis, and chemical degradation and derivatization studies. Stellettapeptins contain numerous nonproteinogenic amino acid residues and they are the first peptides reported to contain a 3-hydroxy-6,8-dimethylnon-4-(Z)-enoic acid moiety. Compounds 1 and 2 potently inhibit infection of human T-lymphoblastoid cells by HIV-1RF with EC50 values of 23 and 27 nM, respectively.

Lipopeptides from the tropical marine cyanobacterium symploca sp.

A collection of the tropical marine cyanobacterium Symploca sp., collected near Kimbe Bay, Papua New Guinea, previously yielded several new metabolites including kimbeamides A-C, kimbelactone A, and tasihalide C. Investigations into a more polar cytotoxic fraction yielded three new lipopeptides, tasiamides C-E (1-3). The planar structures were deduced by 2D NMR spectroscopy and tandem mass spectrometry, and their absolute configurations were determined by a combination of Marfeys and chiral-phase GC-MS analysis. These new metabolites are similar to several previously isolated compounds, including tasiamide (4), grassystatins (5, 6), and symplocin A, all of which were isolated from similar filamentous marine cyanobacteria.

Cytotoxic cyclic depsipeptides from the Australian marine sponge Neamphius huxleyi

Three new cyclic depsipeptides, neamphamides B (2), C (3), and D (4), were isolated from the Australian sponge Neamphius huxleyi. The planar structural characterization of these molecules was elucidated using 2D NMR experiments and ESI-FTICR-MSn. Their configurations were determined by Marfey's method and J-based NMR analysis. These new metabolites inhibited the growth of human cell lines (A549, HeLa, LNCaP, PC3, and NFF) with IC50 values ranging from 88 to 370 nM. However, neamphamide D causes A549 cell proliferation at subcytotoxic doses and should be treated cautiously as a cytotoxic compound.

PROTEASE INHIBITORS, COMPOSITIONS AND METHODS OF USE

This invention relates to grassystatins A, B and C, and their isolated or purified forms. The compounds of the invention are useful as aspartic protease, gamma secretase, or metalloprotease inhibitors. Methods of using the compounds and compositions thereof are also disclosed.

METHOD FOR PREPARING AMIDE

The present invention provides a method for preparing amides, in which an amino acid ionic liquid is used as both a reaction medium and a catalyst to catalyze Beckman rearrangement of a ketoxime, so as to produce an amide. In the method, the rearrangement is conducted by catalyzing a ketoxime with an amino acid ionic liquid having the asymmetric property at a moderate reaction temperature during a short reaction time, so as to produce an amide without adding other catalysts such as concentrate sulfuric acid. The method has advantages such as avoiding corrosion in equipments with pipelines, the high conversion rate of ketoximes and the high selectivity of amides.

Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation

In our efforts to exploremarine cyanobacteria as a source of novel bioactive compounds, we discovered a statine unit-containing linear decadepsipeptide, grassystatin A (1), which we screened against a diverse set of 59 proteases. We describe the structure

The facile production of N-methyl amino acids via oxazolidinones

A range of oxazolidinones derived from N-carbamoyl α-amino acids were prepared by an efficient method as key intermediates in the synthesis of N-methyl amino acids and peptides. The method was readily applied to most α-amino acids except those with basic side chains. The oxazolidinones were converted by reductive cleavage into N-methyl α-amino acids. CSIRO 2000.

Synthesis and structural characterization of N-methyl-DL-glutamic acid

The solid-state conformation of racemic N-methylglutamic acid has been defined by single-crystal X-ray crystallography. Orthorhombic crystals belong to the space group P bca with a 15.219(2), b 10.583(1), c 9.595(1) ? and Z 8. The structure was refined to